Tous Actualités
Suivre
Abonner Solianis Monitoring AG

Solianis Monitoring AG

Solianis Monitoring finalizes clinical trial for non-invasive conti¬nuous glucose monitoring in patients with diabetes

Zurich (ots)

Solianis Monitoring Ltd reaches another milestone
testing their Multisensor Glucose Monitoring System for non-invasive 
continuous glucose monitoring in daily life
The latest generation of Solianis' Multisensor Glucose Monitoring 
System with the final sensor configuration was tested in patients 
with diabetes in daily life. 20 patients wore the device between 
November 2009 and August 2010 for over 1'000 days during their normal
day to day activities. Interim data evaluation shows that the device 
performs reliable and delivers continuous glucose information.
'I am convinced that the glucose information provided by this 
device can improve management of patients with diabetes significantly
and I look forward to explore the integration of this system in my 
clinical routine', says Prof. Marc Donath, University Hospital Basel,
Chief of Department Endocrinology, Diabetology and Metabolism and 
member of Solianis' Scientific Advisory Board.
'These encouraging results are another important step on our route
towards non-invasive continuous glucose monitoring,' states Mario 
Stark, CEO of Solianis Monitoring Ltd. 'We now have the necessary 
data and proof to finalize the first generation system. This is the 
right time for us to engage with a strategic partner to bring the 
Multisensor Glucose Monitoring System to patients with diabetes and 
their caregivers for the benefit of the diabetes community, our 
shareholders and employees.'
Solianis Monitoring Ltd. is a Swiss medical device company 
developing an in¬novative non-invasive Continuous Glucose Monitoring 
(CGM) system for patients with diabetes, their relatives and health 
care professionals. Its unique and proprietary technology is 
integrated in a Multisensor Glucose Monitoring System (MGMS) which 
continuously delivers information on glucose variations. The current 
device is being tested to finalize the design and optimize the 
glucose information.
Solianis was incorporated in May 2005 and has so far been funded 
by private investors, the Pioneer Fond of the Zurich Cantonal Bank 
and the EGS Beteiligungen AG.

Contact:

Media:
Micaela Wochner
Phone: +41/44/306'80'29
Mobile: +41/79/431'79'34
E-Mail: Micaela.wochner@solianis.com

Investors:
Mario Stark
Phone: +41/443/306'80'40
Mobile: +41/79/542'88'74
E-Mail: Mario.stark@solianis.com

Internet: www.solianis.com

Plus de actualités: Solianis Monitoring AG
Plus de actualités: Solianis Monitoring AG